Morbidity Endpoints (ME) in the Amnog Process in Germany- Are me Less Important in Oncology Substances?

May 1, 2016, 00:00
10.1016/j.jval.2016.03.613
https://www.valueinhealthjournal.com/article/S1098-3015(16)00681-1/fulltext
Title : Morbidity Endpoints (ME) in the Amnog Process in Germany- Are me Less Important in Oncology Substances?
Citation : https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(16)00681-1&doi=10.1016/j.jval.2016.03.613
First page : A72
Section Title : Research on Methods - Clinical Outcomes Methods
Open access? : No
Section Order : 1595
Categories :
Tags :
Regions :
ViH Article Tags :